HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2026 — HUTCHMED (China) Limited (“” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today discloses that Professor Mok Shu Kam, Tony has notified the Company he will not stand for re-election following his retirement from the Board at the upcoming annual general meeting (AGM) scheduled for May 12, 2026. Professor Mok has held the position of Independent Non-executive Director for more than eight years, nearing the nine-year tenure limit for independent non-executive directors under the Hong Kong Listing Rules. As a result, he will cease to be an Independent Non-executive Director of the Company once the AGM concludes. Upon his retirement, he will also resign from his roles as chair and member of the Company’s board committees.
In relation to Professor Mok’s planned retirement from the Board, the Board has approved the following adjustments to the board committees’ composition and the appointment of the Senior and Lead Independent Non-executive Director, effective upon the AGM’s conclusion—provided the respective Directors are re-elected by shareholders at the AGM:
(1) Dr Renu Bhatia will be named Senior and Lead Independent Non-executive Director, and appointed as chair of the Nomination Committee;
(2) Dr Chaohong Hu will take on the role of Technical Committee chair; and
(3) Professor Tan Shao Weng, Daniel will be added as a member of the Sustainability Committee.
Dr Bhatia, Dr Hu, and Professor Tan each currently serve as Independent Non-executive Directors of the Company.
Dr Dan Eldar, HUTCHMED’s Chairman, stated: “Professor Mok has served with excellence as an Independent Non-executive Director and chair of both the Nomination Committee and Technical Committee. His leadership has been key to enhancing the Board’s composition and guiding the Company’s scientific and clinical development initiatives. His globally recognized oncology expertise has provided invaluable insights into the Company’s long-term strategy. The Board extends sincere gratitude to Professor Mok for his substantial contributions to the Company’s growth, and we wish him every success in his future endeavors.”
In compliance with Rule 13.51(2) of the Hong Kong Listing Rules, Professor Mok has confirmed he has no disagreements with the Board and that there are no other issues requiring shareholders’ attention regarding his retirement from the Board.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage biopharmaceutical firm. It is dedicated to the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological disorders. Since its founding, the Company has prioritized advancing internally discovered drug candidates to patients worldwide—with its first three medicines launched in China, the first of which is also approved in markets including the U.S., Europe, and Japan. For additional details, visit: or follow us on .
Forward-Looking Statements
This announcement includes forward-looking statements as defined by the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements reflect HUTCHMED’s current expectations about future events. Forward-looking statements involve inherent risks and uncertainties. Such factors include, but are not limited to: the risk that current or future board appointees may not perform effectively in their roles; challenges in identifying and hiring qualified board candidates; and management difficulties that could arise from changes to HUTCHMED’s Board. Existing and potential investors are advised not to place excessive reliance on these forward-looking statements, which are only accurate as of the date of this announcement. For a more detailed discussion of these and other risks, refer to HUTCHMED’s filings with the U.S. Securities and Exchange Commission, on AIM, and with The Stock Exchange of Hong Kong Limited. HUTCHMED does not undertake any duty to update or revise the information in this announcement, whether due to new information, future events, or other circumstances.
CONTACTS
| Investor Enquiries | +852 2121 8200 / |
| Media Enquiries | |
| FTI Consulting – | +44 20 3727 1030 / |
| Ben Atwell / Tim Stamper | +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / |
| Panmure Liberum | Nominated Advisor and Joint Broker |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| Cavendish | Joint Broker |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| Deutsche Numis | Joint Broker |
| Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000 |
